Consensus on infertility treatment related to polycystic ovary syndrome

B. C. Tarlatzis, B. C.J.M. Fauser, R. S. Legro, R. J. Norman, K. Hoeger, R. Pasquali, S. Franks, I. E. Messinis, R. F. Casper, R. Homburg, R. Lobo, R. W. Rebar, R. Fleming, B. R. Carr, Ph Bouchard, J. Chang, J. N. Hugues, Ricardo Azziz, E. M. Kolibianakis, G. Griesinger & 11 others K. Diedrich, A. Balen, C. Farquhar, P. Devroey, P. C. Ho, J. Collins, D. G. Goulis, R. Eijkemans, P. G. Crosignani, A. DeCherney, A. Van Steirteghem

Research output: Contribution to journalArticle

339 Citations (Scopus)

Abstract

The treatment of infertile women with polycystic ovary syndrome (PCOS) is surrounded by many controversies. This paper describes, on the basis of the currently available evidence, the consensus reached by a group of experts regarding the therapeutic challenges raised in these women. Before any intervention is initiated, preconceptional counselling should be provided emphasizing the importance of life style, especially weight reduction and exercise in overweight women, smoking and alcohol consumption. The recommended first-line treatment for ovulation induction remains the anti-estrogen clomiphene citrate (CC). Recommended second-line intervention, should CC fail to result in pregnancy, is either exogenous gonadotrophins or laparoscopic ovarian surgery (LOS). The use of exogenous gonadotrophins is associated with increased chances for multiple pregnancy and, therefore, intense monitoring of ovarian response is required. LOS alone is usually effective in <50% of women and additional ovulation induction medication is required under those circumstances. Overall, ovulation induction (representing the CC, gonadotrophin paradigm) is reported to be highly effective with a cumulative singleton live birth rate of 72%. Recommended third-line treatment is in vitro fertilization. More patient-tailored approaches should be developed for ovulation induction based on initial screening characteristics of women with PCOS. Such approaches may result in deviation from the above mentioned first-, second- or third-line ovulation strategies in well-defined subsets of patients. Metformin use in PCOS should be restricted to women with glucose intolerance. Based on recent data available in the literature, the routine use of this drug in ovulation induction is not recommended. Insufficient evidence is currently available to recommend the clinical use of aromatase inhibitors for routine ovulation induction. Even singleton pregnancies in PCOS are associated with increased health risk for both the mother and the fetus.

Original languageEnglish (US)
Pages (from-to)462-477
Number of pages16
JournalHuman Reproduction
Volume23
Issue number3
DOIs
StatePublished - Jan 1 2008

Fingerprint

Ovulation Induction
Polycystic Ovary Syndrome
Infertility
Consensus
Clomiphene
Gonadotropins
Laparoscopy
Therapeutics
Pregnancy
Multiple Pregnancy
Aromatase Inhibitors
Glucose Intolerance
Birth Rate
Metformin
Live Birth
Fertilization in Vitro
Ovulation
Alcohol Drinking
Life Style
Counseling

Keywords

  • 2007 consensus
  • Infertility treatment
  • Polycystic ovary syndrome

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Tarlatzis, B. C., Fauser, B. C. J. M., Legro, R. S., Norman, R. J., Hoeger, K., Pasquali, R., ... Van Steirteghem, A. (2008). Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction, 23(3), 462-477. https://doi.org/10.1093/humrep/dem426

Consensus on infertility treatment related to polycystic ovary syndrome. / Tarlatzis, B. C.; Fauser, B. C.J.M.; Legro, R. S.; Norman, R. J.; Hoeger, K.; Pasquali, R.; Franks, S.; Messinis, I. E.; Casper, R. F.; Homburg, R.; Lobo, R.; Rebar, R. W.; Fleming, R.; Carr, B. R.; Bouchard, Ph; Chang, J.; Hugues, J. N.; Azziz, Ricardo; Kolibianakis, E. M.; Griesinger, G.; Diedrich, K.; Balen, A.; Farquhar, C.; Devroey, P.; Ho, P. C.; Collins, J.; Goulis, D. G.; Eijkemans, R.; Crosignani, P. G.; DeCherney, A.; Van Steirteghem, A.

In: Human Reproduction, Vol. 23, No. 3, 01.01.2008, p. 462-477.

Research output: Contribution to journalArticle

Tarlatzis, BC, Fauser, BCJM, Legro, RS, Norman, RJ, Hoeger, K, Pasquali, R, Franks, S, Messinis, IE, Casper, RF, Homburg, R, Lobo, R, Rebar, RW, Fleming, R, Carr, BR, Bouchard, P, Chang, J, Hugues, JN, Azziz, R, Kolibianakis, EM, Griesinger, G, Diedrich, K, Balen, A, Farquhar, C, Devroey, P, Ho, PC, Collins, J, Goulis, DG, Eijkemans, R, Crosignani, PG, DeCherney, A & Van Steirteghem, A 2008, 'Consensus on infertility treatment related to polycystic ovary syndrome', Human Reproduction, vol. 23, no. 3, pp. 462-477. https://doi.org/10.1093/humrep/dem426
Tarlatzis BC, Fauser BCJM, Legro RS, Norman RJ, Hoeger K, Pasquali R et al. Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction. 2008 Jan 1;23(3):462-477. https://doi.org/10.1093/humrep/dem426
Tarlatzis, B. C. ; Fauser, B. C.J.M. ; Legro, R. S. ; Norman, R. J. ; Hoeger, K. ; Pasquali, R. ; Franks, S. ; Messinis, I. E. ; Casper, R. F. ; Homburg, R. ; Lobo, R. ; Rebar, R. W. ; Fleming, R. ; Carr, B. R. ; Bouchard, Ph ; Chang, J. ; Hugues, J. N. ; Azziz, Ricardo ; Kolibianakis, E. M. ; Griesinger, G. ; Diedrich, K. ; Balen, A. ; Farquhar, C. ; Devroey, P. ; Ho, P. C. ; Collins, J. ; Goulis, D. G. ; Eijkemans, R. ; Crosignani, P. G. ; DeCherney, A. ; Van Steirteghem, A. / Consensus on infertility treatment related to polycystic ovary syndrome. In: Human Reproduction. 2008 ; Vol. 23, No. 3. pp. 462-477.
@article{a4efd39cbe0f44878781de7ea935c422,
title = "Consensus on infertility treatment related to polycystic ovary syndrome",
abstract = "The treatment of infertile women with polycystic ovary syndrome (PCOS) is surrounded by many controversies. This paper describes, on the basis of the currently available evidence, the consensus reached by a group of experts regarding the therapeutic challenges raised in these women. Before any intervention is initiated, preconceptional counselling should be provided emphasizing the importance of life style, especially weight reduction and exercise in overweight women, smoking and alcohol consumption. The recommended first-line treatment for ovulation induction remains the anti-estrogen clomiphene citrate (CC). Recommended second-line intervention, should CC fail to result in pregnancy, is either exogenous gonadotrophins or laparoscopic ovarian surgery (LOS). The use of exogenous gonadotrophins is associated with increased chances for multiple pregnancy and, therefore, intense monitoring of ovarian response is required. LOS alone is usually effective in <50{\%} of women and additional ovulation induction medication is required under those circumstances. Overall, ovulation induction (representing the CC, gonadotrophin paradigm) is reported to be highly effective with a cumulative singleton live birth rate of 72{\%}. Recommended third-line treatment is in vitro fertilization. More patient-tailored approaches should be developed for ovulation induction based on initial screening characteristics of women with PCOS. Such approaches may result in deviation from the above mentioned first-, second- or third-line ovulation strategies in well-defined subsets of patients. Metformin use in PCOS should be restricted to women with glucose intolerance. Based on recent data available in the literature, the routine use of this drug in ovulation induction is not recommended. Insufficient evidence is currently available to recommend the clinical use of aromatase inhibitors for routine ovulation induction. Even singleton pregnancies in PCOS are associated with increased health risk for both the mother and the fetus.",
keywords = "2007 consensus, Infertility treatment, Polycystic ovary syndrome",
author = "Tarlatzis, {B. C.} and Fauser, {B. C.J.M.} and Legro, {R. S.} and Norman, {R. J.} and K. Hoeger and R. Pasquali and S. Franks and Messinis, {I. E.} and Casper, {R. F.} and R. Homburg and R. Lobo and Rebar, {R. W.} and R. Fleming and Carr, {B. R.} and Ph Bouchard and J. Chang and Hugues, {J. N.} and Ricardo Azziz and Kolibianakis, {E. M.} and G. Griesinger and K. Diedrich and A. Balen and C. Farquhar and P. Devroey and Ho, {P. C.} and J. Collins and Goulis, {D. G.} and R. Eijkemans and Crosignani, {P. G.} and A. DeCherney and {Van Steirteghem}, A.",
year = "2008",
month = "1",
day = "1",
doi = "10.1093/humrep/dem426",
language = "English (US)",
volume = "23",
pages = "462--477",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Consensus on infertility treatment related to polycystic ovary syndrome

AU - Tarlatzis, B. C.

AU - Fauser, B. C.J.M.

AU - Legro, R. S.

AU - Norman, R. J.

AU - Hoeger, K.

AU - Pasquali, R.

AU - Franks, S.

AU - Messinis, I. E.

AU - Casper, R. F.

AU - Homburg, R.

AU - Lobo, R.

AU - Rebar, R. W.

AU - Fleming, R.

AU - Carr, B. R.

AU - Bouchard, Ph

AU - Chang, J.

AU - Hugues, J. N.

AU - Azziz, Ricardo

AU - Kolibianakis, E. M.

AU - Griesinger, G.

AU - Diedrich, K.

AU - Balen, A.

AU - Farquhar, C.

AU - Devroey, P.

AU - Ho, P. C.

AU - Collins, J.

AU - Goulis, D. G.

AU - Eijkemans, R.

AU - Crosignani, P. G.

AU - DeCherney, A.

AU - Van Steirteghem, A.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The treatment of infertile women with polycystic ovary syndrome (PCOS) is surrounded by many controversies. This paper describes, on the basis of the currently available evidence, the consensus reached by a group of experts regarding the therapeutic challenges raised in these women. Before any intervention is initiated, preconceptional counselling should be provided emphasizing the importance of life style, especially weight reduction and exercise in overweight women, smoking and alcohol consumption. The recommended first-line treatment for ovulation induction remains the anti-estrogen clomiphene citrate (CC). Recommended second-line intervention, should CC fail to result in pregnancy, is either exogenous gonadotrophins or laparoscopic ovarian surgery (LOS). The use of exogenous gonadotrophins is associated with increased chances for multiple pregnancy and, therefore, intense monitoring of ovarian response is required. LOS alone is usually effective in <50% of women and additional ovulation induction medication is required under those circumstances. Overall, ovulation induction (representing the CC, gonadotrophin paradigm) is reported to be highly effective with a cumulative singleton live birth rate of 72%. Recommended third-line treatment is in vitro fertilization. More patient-tailored approaches should be developed for ovulation induction based on initial screening characteristics of women with PCOS. Such approaches may result in deviation from the above mentioned first-, second- or third-line ovulation strategies in well-defined subsets of patients. Metformin use in PCOS should be restricted to women with glucose intolerance. Based on recent data available in the literature, the routine use of this drug in ovulation induction is not recommended. Insufficient evidence is currently available to recommend the clinical use of aromatase inhibitors for routine ovulation induction. Even singleton pregnancies in PCOS are associated with increased health risk for both the mother and the fetus.

AB - The treatment of infertile women with polycystic ovary syndrome (PCOS) is surrounded by many controversies. This paper describes, on the basis of the currently available evidence, the consensus reached by a group of experts regarding the therapeutic challenges raised in these women. Before any intervention is initiated, preconceptional counselling should be provided emphasizing the importance of life style, especially weight reduction and exercise in overweight women, smoking and alcohol consumption. The recommended first-line treatment for ovulation induction remains the anti-estrogen clomiphene citrate (CC). Recommended second-line intervention, should CC fail to result in pregnancy, is either exogenous gonadotrophins or laparoscopic ovarian surgery (LOS). The use of exogenous gonadotrophins is associated with increased chances for multiple pregnancy and, therefore, intense monitoring of ovarian response is required. LOS alone is usually effective in <50% of women and additional ovulation induction medication is required under those circumstances. Overall, ovulation induction (representing the CC, gonadotrophin paradigm) is reported to be highly effective with a cumulative singleton live birth rate of 72%. Recommended third-line treatment is in vitro fertilization. More patient-tailored approaches should be developed for ovulation induction based on initial screening characteristics of women with PCOS. Such approaches may result in deviation from the above mentioned first-, second- or third-line ovulation strategies in well-defined subsets of patients. Metformin use in PCOS should be restricted to women with glucose intolerance. Based on recent data available in the literature, the routine use of this drug in ovulation induction is not recommended. Insufficient evidence is currently available to recommend the clinical use of aromatase inhibitors for routine ovulation induction. Even singleton pregnancies in PCOS are associated with increased health risk for both the mother and the fetus.

KW - 2007 consensus

KW - Infertility treatment

KW - Polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=40749085240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40749085240&partnerID=8YFLogxK

U2 - 10.1093/humrep/dem426

DO - 10.1093/humrep/dem426

M3 - Article

VL - 23

SP - 462

EP - 477

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 3

ER -